Eupraxia Pharmaceuticals Inc., a Vancouver based developer of a novel platform that modulates drug release with precision, has raised $1.97 million from 15 BC investors.
Eupraxia Pharmaceuticals has raised $4.474 million since 2016.
Eupraxia Pharmaceuticals’ lead product candidate, EP-104IAR, is a locally delivered, sustained-release, non-opioid treatment for pain related to osteoarthritis.